Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases.

Ochs HD, Melamed I, Borte M, Moy JN, Pyringer B, D Kobayashi AL, Knutsen AP, Smits W, Pituch-Noworolska A, Kobayashi RH.

Immunotherapy. 2018 Oct;10(14):1193-1202. doi: 10.2217/imt-2018-0074. Epub 2018 Aug 8.

2.

Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study.

Melamed IR, Borte M, Trawnicek L, Kobayashi AL, Kobayashi RH, Knutsen A, Gupta S, Smits W, Pituch-Noworolska A, Strach M, Pulka G, Ochs HD, Moy JN.

Eur J Pharm Sci. 2018 Jun 15;118:80-86. doi: 10.1016/j.ejps.2018.03.007. Epub 2018 Mar 6.

3.

A pilot study of high-dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation.

Melamed IR, Heffron M, Testori A, Lipe K.

Autism Res. 2018 Mar;11(3):421-433. doi: 10.1002/aur.1906. Epub 2018 Feb 10.

PMID:
29427532
4.

A multidisciplinary approach for the treatment of young patients with suprasellar osteochondroma.

Zanotti MC, Melamed I, Diomin V, Walter E, Baraf L, Frenkel M, Shelef I.

Childs Nerv Syst. 2018 Mar;34(3):559-563. doi: 10.1007/s00381-017-3619-3. Epub 2017 Oct 24.

PMID:
29067502
5.

Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials".

Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, Darter A, Bourgeois C, Fritsch S, Leibl H, McCoy B, Gelmont D, Yel L.

J Clin Immunol. 2017 Nov;37(8):739-740. doi: 10.1007/s10875-017-0438-y. Epub 2017 Sep 5. No abstract available.

6.

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.

Borte M, Melamed IR, Pulka G, Pyringer B, Knutsen AP, Ochs HD, Kobayashi RH, Kobayashi AL, Gupta S, Strach M, Smits W, Pituch-Noworolska A, Moy JN.

J Clin Immunol. 2017 Aug;37(6):603-612. doi: 10.1007/s10875-017-0424-4. Epub 2017 Jul 29.

7.

[An ethics call to include pregnant women in research: Reflections from the Global Forum on Bioethics in Research].

Saenz C, Alger J, Beca JP, Belizán JM, Cafferata ML, Guzmán JAC, Candanedo P JE, Duque L, Figueroa L, Garcés A, Gresh L, Gubert IC, Guilhem D, Guz G, Kaltwasser G, Lescano AR, Luna F, Cardelli AAM, Mastroleo I, Melamed IN, Del Carpio Toia AM, Palacios R, Palma GI, Salas SP, Sandoval X, de Siqueira SS, Vásquez H, de Vega BMV.

Rev Panam Salud Publica. 2017;41. pii: e13. Epub 2017 Feb 8. Spanish. No abstract available.

8.

Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency.

Wasserman RL, Melamed IR, Stein MR, Jolles S, Norton M, Moy JN; GMX07 Study Group.

J Clin Immunol. 2017 Aug;37(6):613. doi: 10.1007/s10875-017-0418-2. No abstract available.

PMID:
28714047
9.

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency.

Wasserman RL, Melamed IR, Stein MR, Jolles S, Norton M, Moy JN; GMX07 Study Group.

J Clin Immunol. 2017 Apr;37(3):301-310. doi: 10.1007/s10875-017-0383-9. Epub 2017 Mar 18. Erratum in: J Clin Immunol. 2017 Jul 17;:.

10.

Neurologic manifestations of hereditary angioedema.

Testori A, Melamed I.

Ann Allergy Asthma Immunol. 2017 Jan;118(1):119-120. doi: 10.1016/j.anai.2016.10.016. No abstract available. Erratum in: Ann Allergy Asthma Immunol. 2017 Apr;118(4):527.

PMID:
28007084
11.

Attention Deficit Disorder and Allergic Rhinitis: Are They Related?

Melamed I, Heffron M.

J Immunol Res. 2016;2016:1596828. Epub 2016 Oct 31.

12.

Diagnosing necrotic meningioma: a distinctive imaging pattern in diffusion MRI and MR spectroscopy.

Ben-Arie G, Serlin Y, Ivens S, Benifla M, Cagnano E, Melamed I, Merkin V, Shelef I.

Neuroradiol J. 2017 Feb;30(1):57-61. doi: 10.1177/1971400916678241. Epub 2016 Nov 19.

13.

Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.

Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, Darter A, Bourgeois C, Fritsch S, Leibl H, McCoy B, Gelmont D, Yel L.

J Clin Immunol. 2016 Oct;36(7):700-12. doi: 10.1007/s10875-016-0327-9. Epub 2016 Aug 31.

14.

Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.

Wasserman RL, Melamed I, Kobrynski L, Puck J, Gupta S, Doralt J, Sharkhawy M, Engl W, Leibl H, Gelmont D, Yel L.

Immunotherapy. 2016 Oct;8(10):1175-86. doi: 10.2217/imt-2016-0066. Epub 2016 Jul 28.

15.

Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.

Heimall J, Chen J, Church JA, Griffin R, Melamed I, Kleiner GI.

J Clin Immunol. 2016 Aug;36(6):600-9. doi: 10.1007/s10875-016-0311-4. Epub 2016 Jun 25.

PMID:
27342758
16.

Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease.

Wasserman RL, Lumry W, Harris J 3rd, Levy R, Stein M, Forbes L, Cunningham-Rundles C, Melamed I, Kobayashi AL, Du W, Kobayashi R.

J Clin Immunol. 2016 Aug;36(6):590-9. doi: 10.1007/s10875-016-0308-z. Epub 2016 Jun 20.

17.

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.

Wasserman RL, Melamed I, Stein MR, Engl W, Sharkhawy M, Leibl H, Puck J, Rubinstein A, Kobrynski L, Gupta S, Grant AJ, Ratnayake A, Richmond WG, Church J, Yel L, Gelmont D.

J Clin Immunol. 2016 Aug;36(6):571-82. doi: 10.1007/s10875-016-0298-x. Epub 2016 May 25.

18.

Beyond Bioethics: A Child Rights-Based Approach to Complex Medical Decision-Making.

Wade K, Melamed I, Goldhagen J.

Perspect Biol Med. 2016;58(3):332-40. doi: 10.1353/pbm.2016.0009.

PMID:
27157351
19.

The Potential Value of the U.N. Convention on the Rights of the Child in Pediatric Bioethics Settings.

Silva MD, Lew CD, Lundy L, Lang KR, Melamed I, Shaul RZ.

Perspect Biol Med. 2016;58(3):290-305. doi: 10.1353/pbm.2016.0012.

PMID:
27157346
20.

Dural sinus obstruction following head injury: a diagnostic and clinical study.

Benifla M, Yoel U, Melamed I, Merkin V, Cohen A, Shelef I.

J Neurosurg Pediatr. 2016 Sep;18(3):253-62. doi: 10.3171/2016.3.PEDS15690. Epub 2016 May 6.

PMID:
27153380
21.

Free craniotomy versus osteoplastic craniotomy, assessment of flap viability using 99mTC MDP SPECT.

Shelef I, Golan H, Merkin V, Melamed I, Benifla M.

J Clin Neurosci. 2016 Sep;31:63-6. doi: 10.1016/j.jocn.2015.11.031. Epub 2016 Apr 8.

PMID:
27068014
22.

Supraciliary keyhole craniotomy for anterior frontal lesions in children.

Benifla M, Merkin V, Rosenthal G, Shoshan Y, Melamed I.

J Clin Neurosci. 2016 Apr;26:37-41. doi: 10.1016/j.jocn.2015.10.024. Epub 2016 Jan 4.

PMID:
26758703
23.

Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases.

Melamed IR, Gupta S, Stratford Bobbitt M, Hyland N, Moy JN.

Clin Exp Immunol. 2016 May;184(2):228-36. doi: 10.1111/cei.12760. Epub 2016 Feb 15.

24.

A new subset of common variable immune deficiency characterized by reduced C1 esterase inhibitor levels.

Melamed IR, Heffron M, McGee S, Ulltate Sanz L, Testori A.

Ann Allergy Asthma Immunol. 2015 Jul;115(1):83-4. doi: 10.1016/j.anai.2015.04.023. No abstract available.

PMID:
26123426
25.

Mast cells, brain inflammation and autism.

Theoharides TC, Stewart JM, Panagiotidou S, Melamed I.

Eur J Pharmacol. 2016 May 5;778:96-102. doi: 10.1016/j.ejphar.2015.03.086. Epub 2015 May 1. Review.

PMID:
25941080
26.

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033.

Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L, Zhao J, Parr E, Cadavid D.

Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(2):e18. doi: 10.1212/NXI.0000000000000018. eCollection 2014 Aug.

27.

X-microstenting and transmesh coiling in the management of wide-necked tent-like anterior communicating artery aneurysms.

Cohen JE, Melamed I, Itshayek E.

J Clin Neurosci. 2014 Apr;21(4):664-7. doi: 10.1016/j.jocn.2013.09.003. Epub 2013 Nov 28.

PMID:
24291480
28.

Cell-free DNA as a potential marker to predict carbon tetrachloride-induced acute liver injury in rats.

Gruenbaum BF, Boyko M, Delgado B, Douvdevany A, Gruenbaum SE, Melamed I, Gideon M, Cesnulis E, Shapira Y, Zlotnik A.

Hepatol Int. 2013 Jun;7(2):721-7. doi: 10.1007/s12072-012-9414-z. Epub 2012 Nov 22.

PMID:
26201806
29.

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.

Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F.

Lancet Neurol. 2013 Mar;12(3):233-43. doi: 10.1016/S1474-4422(13)70014-0. Epub 2013 Jan 31.

30.

The role of hypothermia in the regulation of blood glutamate levels in naive rats.

Boyko M, Kuts R, Gruenbaum BF, Melamed I, Gruenbaum SE, Klein M, Shapira Y, Zlotnik A.

J Neurosurg Anesthesiol. 2013 Apr;25(2):174-83. doi: 10.1097/ANA.0b013e31827ee0ac.

PMID:
23295267
31.

Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease.

Melamed I, Testori A, Spirer Z.

Int Rev Immunol. 2012 Dec;31(6):451-61. doi: 10.3109/08830185.2012.732631. Review.

PMID:
23215767
32.

The neuro-behavioral profile in rats after subarachnoid hemorrhage.

Boyko M, Azab AN, Kuts R, Gruenbaum BF, Gruenbaum SE, Melamed I, Brotfain E, Shapira Y, Cesnulis E, Zlotnik A.

Brain Res. 2013 Jan 23;1491:109-16. doi: 10.1016/j.brainres.2012.10.061. Epub 2012 Nov 2.

PMID:
23123210
33.

Pharmacokinetics of glutamate-oxaloacetate transaminase and glutamate-pyruvate transaminase and their blood glutamate-lowering activity in naïve rats.

Boyko M, Stepensky D, Gruenbaum BF, Gruenbaum SE, Melamed I, Ohayon S, Glazer M, Shapira Y, Zlotnik A.

Neurochem Res. 2012 Oct;37(10):2198-205. doi: 10.1007/s11064-012-0843-9. Epub 2012 Jul 31.

PMID:
22846966
34.

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.

Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, Leibl H, McCoy B, Empson VG, Gelmont D, Schiff RI; IGSC, 10% with rHuPH20 Study Group.

J Allergy Clin Immunol. 2012 Oct;130(4):951-7.e11. doi: 10.1016/j.jaci.2012.06.021. Epub 2012 Jul 28.

PMID:
22846381
35.

The effect of blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome in a rat model of subarachnoid hemorrhage.

Boyko M, Melamed I, Gruenbaum BF, Gruenbaum SE, Ohayon S, Leibowitz A, Brotfain E, Shapira Y, Zlotnik A.

Neurotherapeutics. 2012 Jul;9(3):649-57. doi: 10.1007/s13311-012-0129-6.

36.

Novel use of an exchange catheter to facilitate intubation with an Aintree catheter in a tall patient with a predicted difficult airway: a case report.

Gruenbaum SE, Gruenbaum BF, Tsaregorodtsev S, Dubilet M, Melamed I, Zlotnik A.

J Med Case Rep. 2012 Apr 13;6:108. doi: 10.1186/1752-1947-6-108.

37.

Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.

Wasserman RL, Church JA, Stein M, Moy J, White M, Strausbaugh S, Schroeder H, Ballow M, Harris J, Melamed I, Elkayam D, Lumry W, Suez D, Rehman SM.

J Clin Immunol. 2012 Aug;32(4):663-9. doi: 10.1007/s10875-012-9656-5. Epub 2012 Mar 6.

38.

Cell-free DNA as a marker for prediction of brain damage in traumatic brain injury in rats.

Ohayon S, Boyko M, Saad A, Douvdevani A, Gruenbaum BF, Melamed I, Shapira Y, Teichberg VI, Zlotnik A.

J Neurotrauma. 2012 Jan 20;29(2):261-7. doi: 10.1089/neu.2011.1938. Epub 2011 Dec 7.

PMID:
22149927
39.

Pyruvate's blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke.

Boyko M, Zlotnik A, Gruenbaum BF, Gruenbaum SE, Ohayon S, Kuts R, Melamed I, Regev A, Shapira Y, Teichberg VI.

Eur J Neurosci. 2011 Nov;34(9):1432-41. doi: 10.1111/j.1460-9568.2011.07864.x. Epub 2011 Sep 21.

PMID:
21936878
40.

Trends over time in the management of 2253 patients with cerebral aneurysms: A single practice experience.

Payner TD, Melamed I, Ansari S, Leipzig TJ, Scott JA, Denardo AJ, Horner TG, Redelman K, Cohen-Gadol AA.

Surg Neurol Int. 2011;2:110. doi: 10.4103/2152-7806.83728. Epub 2011 Aug 13.

41.

Cell-free DNA--a marker to predict ischemic brain damage in a rat stroke experimental model.

Boyko M, Ohayon S, Goldsmith T, Douvdevani A, Gruenbaum BF, Melamed I, Knyazer B, Shapira Y, Teichberg VI, Elir A, Klein M, Zlotnik A.

J Neurosurg Anesthesiol. 2011 Jul;23(3):222-8. doi: 10.1097/ANA.0b013e31821b536a.

PMID:
21593692
42.

Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.

Wasserman RL, Melamed I, Nelson RP Jr, Knutsen AP, Fasano MB, Stein MR, Rojavin MA, Church JA.

Clin Pharmacokinet. 2011 Jun;50(6):405-14. doi: 10.2165/11587030-000000000-00000.

PMID:
21553933
43.

Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease.

Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, Engl W, Leibl H, Sobolevsky L, Gelmont D, Schiff RI, Grossman WJ.

J Clin Immunol. 2011 Jun;31(3):323-31. doi: 10.1007/s10875-011-9512-z. Epub 2011 Mar 22.

PMID:
21424824
44.

[Urgent removal of ruptured cerebral arteriovenous malformations in children].

Benifla M, Shelef I, Melamed I, Merkin V, Barrelly R, Cohen A.

Harefuah. 2010 Mar;149(3):148-52, 195. Hebrew.

PMID:
20684164
45.

Optimizing referral practices for patients with non-traumatic intracerebral hemorrhage.

Litofsky NS, Matthews J, Wolak ML, Shah MM, Melamed I, Thombs LA.

Mo Med. 2010 May-Jun;107(3):210-6.

46.

Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.

Hagan JB, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, Zenker O, Orange JS.

J Clin Immunol. 2010 Sep;30(5):734-45. doi: 10.1007/s10875-010-9423-4. Epub 2010 May 8.

47.
48.

Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.

Wasserman RL, Church JA, Peter HH, Sleasman JW, Melamed I, Stein MR, Bichler J; IgPro10 in PID Study group.

Eur J Pharm Sci. 2009 Jun 28;37(3-4):272-8. doi: 10.1016/j.ejps.2009.02.014. Epub 2009 Mar 6.

PMID:
19491015
49.

Trans-zygomatic middle cranial fossa approach to access lesions around the cavernous sinus and anterior parahippocampus: a minimally invasive skull base approach.

Melamed I, Tubbs RS, Payner TD, Cohen-Gadol AA.

Acta Neurochir (Wien). 2009 Aug;151(8):977-82; discussion 982. doi: 10.1007/s00701-009-0376-4. Epub 2009 May 9.

PMID:
19430721
50.

Unilateral partial hemilaminectomy for disc removal in a 1-year-old child.

Benifla M, Melamed I, Barrelly R, Aloushin A, Shelef I.

J Neurosurg Pediatr. 2008 Aug;2(2):133-5. doi: 10.3171/PED/2008/2/8/133.

PMID:
18671619

Supplemental Content

Loading ...
Support Center